Risk factor
Very vulnerable to price shocks
Profitability factor
Favourable analyst view
About
Bonesupport Holding AB (publ) is a specialized orthobiologics firm dedicated to the creation and global commercialization of injectable bioceramic bone graft substitutes, designed to effectively treat bone voids. Its innovative solutions are distributed across Europe, North America, and other international territories. The company's key offerings include CERAMENT Bone Void Filler, a synthetic, injectable material that is both moldable and drillable, formulated with hydroxyapatite, calcium sulfate, and the radiopaque agent iohexol. Furthermore, Bonesupport provides CERAMENT G, a ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Beyond its current product line, Bonesupport is actively engaged in preclinical research to develop novel candidates aimed at promoting bone regeneration. This research targets challenging conditions such as trauma, revision arthroplasty, chronic osteomyelitis, various oncological applications, and bone and foot infections often associated with diabetes. Established in 1999, the company is headquartered in Lund, Sweden.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of BONEX.ST is 357 and suggests 58% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc